Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326353 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL2326345 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL5143661 | 0.78 | NPSR1 (0.50) | SMN1; SMN2TSHRHCAR2ALDH1A1ALOX15 | |
| SCHEMBL12213573 | 0.78 | NPSR1 (0.50) | SMN1; SMN2TSHRHCAR2ALDH1A1ALOX15 | |
| SCHEMBL5143663 | 0.78 | NPSR1 (0.50) | SMN1; SMN2TSHRHCAR2ALDH1A1ALOX15 | |
| SCHEMBL11707587 | 0.77 | — | — | |
| SCHEMBL11708371 | 0.77 | HCAR2 (0.46) | SMN1; SMN2TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL1739 | 0.77 | — | — | |
| SCHEMBL1740 | 0.77 | — | — | |
| SCHEMBL12431015 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012176830-A1 | 1,2-BIS(DIALKYLPHOSPHINO)-4,5-(METHYLENEDIOXY)BENZENE DERIVATIVE, METHOD FOR MANUFACTURING SAME, METAL COMPLEX HAVING THIS 1,2-BIS(DIALKYLPHOSPHINO)-4,5-(METHYLENEDIOXY)BENZENE DERIVATIVE AS A LIGAND, AND ASYMMETRIC HYDROGENATION METHOD | 日本化学工業株式会社 (JP) | 2012-12-27 | — | — | WO | disclosed |
| EP-2534161-A1 | ENANTIOMERICALLY ENRICHED AMINODIPHOSPHINES AS LIGANDS FOR THE PREPARATION OF CATALYSTS FOR ASYMMETRIC SYNTHESIS | Enantia, S.L. (ES) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309997-A1 | Enantiomerically Enriched Aminodiphosphines as Ligands for the Preparation of Catalysts for Asymmetric Synthesis | ENANTIA, S.L. (ES) | 2012-12-06 | — | — | US | disclosed |
| US-20120309997-A1 | Enantiomerically Enriched Aminodiphosphines as Ligands for the Preparation of Catalysts for Asymmetric Synthesis | ENANTIA, S.L. (ES) | 2012-12-06 | — | — | US | disclosed |
| WO-2011098160-A1 | ENANTIOMERICALLY ENRICHED AMINODIPHOSPHINES AS LIGANDS FOR THE PREPARATION OF CATALYSTS FOR ASYMMETRIC SYNTHESIS | ENANTIA, S.L. (ES) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098160-A1 | ENANTIOMERICALLY ENRICHED AMINODIPHOSPHINES AS LIGANDS FOR THE PREPARATION OF CATALYSTS FOR ASYMMETRIC SYNTHESIS | ENANTIA, S.L. (ES) | 2011-08-18 | — | — | WO | disclosed |
| US-20070197799-A1 | Novel bisphosphane catalysts | DEGUSSA GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20060183930-A1 | Chiral monophosphorus compounds | DREISBACH CLAUS | 2006-08-17 | — | — | US | disclosed |
| US-7057061-B2 | Chiral monophosphorus compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20030119664-A1 | Chiral monophosphorus compounds | LANXESS DEUTSCHLAND GMBH (DE) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197799-A1 | Novel bisphosphane catalysts | BPGM, BCAT2, BCAT1 | SMN1; SMN2 3430/4885TSHR 3358/4885HCAR2 3651/4885 |
| US-20120309997-A1 | Enantiomerically Enriched Aminodiphosphines as Ligands for the Preparation of Catalysts for Asymmetric Synthesis | PHOSPHO1, AASDHPPT, AGPS | SMN1; SMN2 4541/4885TSHR 4609/4885HCAR2 4276/4885 |
| US-20060183930-A1 | Chiral monophosphorus compounds | PNP, MTAP, MDM4 | SMN1; SMN2 4415/4885TSHR 4870/4885HCAR2 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.